Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31685 total
Vor Biopharma shares closed at $19.03 on Tuesday, up 5.5% on the day but barely moved on the week, down 0.2%, while its closest clinical-stage peers posted a median gain of 6.4% over the same period. Short interest has…
Hims & Hers Health heads into its November 2 earnings report with a founder reducing his stake, shorts stubbornly high but quietly pulling back, and a Street consensus that has yet to commit to the growth story. The…
DoorDash fell 0.7% over the past week while its closest correlated peers posted a median gain of 3.6%, a gap that puts the delivery platform among the week's notable underperformers in its own group. Expedia led the…
Damora Therapeutics heads into its November 4 earnings with two activists on its 13D register, a short position exceeding the entire free float, and retail attention running at a three-standard-deviation spike above…
Array Technologies is caught in a tightening vise: short interest nudged higher again this week, analysts keep cutting targets, and the passive index deletion timeline is now measured in weeks rather than months. Short…
JFrog, the DevOps and software supply chain platform, fell 7% over the past week to $92.37, broadly in line with a rough stretch for cybersecurity and infrastructure software peers, yet the signals underneath the…
VTRS enters the final stretch before its November 5 earnings print with a fresh target-price raise from JP Morgan this morning and a 15-day countdown that is sharpening the focus on what the Street expects from the…
Cogent Biosciences has snapped back 11% in a week, and the bears who spent the summer building their position are now quietly retreating ahead of a November 2 earnings date that also carries FDA pipeline catalysts. The…
Albertsons Companies has had an unusually active week for a mid-cap grocer: the stock climbed nearly 6% to $13.47, outpacing a peer group that barely moved, while analysts at three major firms moved their ratings on…
Sphere Entertainment Co. jumped 10.1% over the past week to close at $112.84, a sharp reversal after a month that stripped nearly 22% from the stock, yet the short position barely flinched, leaving the two sides of the…
Short sellers have been rebuilding positions in PCOR at an unusually fast clip. Short interest has climbed 28.5% over the past month to 19.7 million shares, or 12.7% of the free float, one of the more aggressive…
Vertiv Holdings slid 14.2% on the week to $203.56, a steeper drop than most of its closest peers, yet short positioning and the borrow market remain notably uncrowded for a stock that just delivered that kind of…
Weatherford International has printed its Q3 results and bounced, yet short sellers are still adding to positions, creating the week's central tension on this stock. The shares closed at $79.34 on October 20, up nearly…
The most striking development for BUG this week is not the ETF's 7% pullback but the coincidence of three signals all flipping in the same direction at once: short interest has nearly tripled in a month, options buyers…
Revolution Medicines gained nearly 8% on Tuesday to close at $196.55, its biggest single-day move in weeks, arriving just 15 days before its November 5 earnings date with analyst conviction at its highest in…
GFL Environmental Inc. reports Q3 results on October 28 with short sellers cutting positions at their sharpest monthly rate in years, leaving the lending market looser than it has been in months. The most striking…
Blackstone reported Q3 results on Thursday and the stock has responded: shares closed at $110.34 on Tuesday, up 3% on the day and recovering from levels that had briefly dipped below $107 in the immediate post-earnings…
DT slipped 1.3% over the past week to $63.64, a notable underperformance against a median gain of 4.6% for its eight closest software peers, yet the Street chose the same moment to raise price targets across the…
Mirum Pharmaceuticals closed Tuesday at $85.07, up 6.8% on the week, yet eight analysts have raised their price targets over the past two weeks without a single downgrade, leaving the stock trading at roughly a 45%…
BridgeBio Pharma enters the week with an interesting tension: short sellers hold a meaningful 10.6% of the free float, yet that position has been quietly shrinking while the stock has gained 6.7% over the past five…
